Oncolix, Inc.

Oncolix, Inc.

Oncolix is a biotechnology company that is developing Prolanta for ovarian and breast cancer. Prolanta is a first-in-class prolactin  receptor antagonist that induces apoptosis of cancerous cells. The drug also has anti-HER2 activity. Prolanta is currently in late preclinical studies (non-human primates) and is expected to be evaluated in human clinical trials in early 2011. 

Michael Redman
14405 Walters Road, Suite 1108
Houston TX 77014
(281) 923-2807